Read Article

Supporting international business matching, LSMIP propritizes "Speed" and "Accuracy" in out service.
Please be noted that contents are in English/Japanese, translated on a request basis from authors/members.
国際間のビジネス・マッチングを促進するため、LSMIPでは情報発信の迅速性・正確性を重視しております。
コンテンツは各言語(英語、日本語)でお読みいただけますが、必要に応じて翻訳する場合があります。

Overview

0

[Yakuji Nippo]Joint research between industry-academia-government to create new drugs-Building an integrated database of disease-specific information

Seven member companies of the Japan Pharmaceutical Manufacturers Association (JPMA) and the National Center Biobank Network (NCBN) announced on December...
  • Target market
    Japan
  • Business category
    Pharmaceutical, Biopharmaceutical, Regerative medicine, Medical device, Digital health, Others
  • Business function
    Marketing >
  • Keyword
  • Author
    "LSMIP Editorial Office" of "CM Plus Corporation"
  • Availability
    Membership

Detail


株式会社薬事日報社から許諾を受けて、株式会社シーエムプラスが英語に翻訳しております。
オリジナルの正式言語は日本語であり、内容および解釈については日本語が優先されます。
With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

 

JPMA / NCBN
Joint research between industry-academia-government to create new drugs-Building an integrated database of disease-specific information

January 27th, 2021 

Seven member companies of  the Japan Pharmaceutical Manufacturers Association (JPMA) and the National Center Biobank Network (NCBN) announced on December 25 that they will start joint research on building and utilizing an integrated database of disease-specific information that is expected to be used in developing  new drugs and personalized medicine. The joint research is carried out until March 2025. After obtaining omics data such as genetic information and protein from patient-derived samples attached to clinical information held by NCBN, industry-academia-government jointly builds an integrated database of disease-specific information by combining analysis results with clinical information such as laboratory data and image data.
 

(Continue to the next)


For this translated article in English, CM Plus Corporation shall have the copyright.
Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2021 LSMIP office / CM Plus Singapore Pte. Ltd.

Comments (Require approval)

What information are you looking for in articles?
Let us help you to find out the articles for your business requirements!
Like many other companies, we use cookies and other technologies, some of which are essential to make our website work. By clicking Accept or continuing to use our site, you agree to use these cookies and other technologies. To learn more, check out our privacy policy.
Accept